BioMed Research International / 2014 / Article / Tab 2

Research Article

Hyperuricemic PRP in Tendon Cells

Table 2

Relative gene expression normalised to the mean of GAPDH and TBP () given as medians and 25–75 percentiles.

Cell donorSCXHAS2COLA1COLA3COMPDCNIL6COX2IL8ACANTGF-b1

T10.073
(0.057–0.113)
1.308
(0.816–1.610)
158.67
(136.07–166.94)
7.052
(3.252–11.519)
0.025
(0.020–0.030)
2.256
(1.670–2.789)
0.166
(0.149–0.172)
0.088
(0.037–0.112)
0.045
(0.039–0.057)
0.0202
(0.0124–0.0342)
0.6676
(0.4728–1.3547)

T20.049
(0.035–0.068)
1.710
(1.493–2.232)
74.792
(40.05–113.63)
3.558
(2.831–5.468)
0.025
(0.023–0.038)
1.697
(1.444–2.216)
0.805
(0.481–1.254)
0.149
(0.117–0.227)
2.058
(1.885–2.480)
0.007
(0.006–0.008)
0.590
(0.504–0.676)

T30.005
(0.003–0.136)
2.055
(1.909–2.974)
137.16
(104.5–154.5)
1.517
(1.174–1.60)
2.003
(1.91–5.17)
0. 489
(0.419–0.854)
0.052
(0.032–0.076)
0.048
(0.045–0.343)
0.02
(0.016–0.159)
0.568
(0.172–0.812)
0.828
(0.616–10.98)

Relative expression levels of tendon cells from three donors (T1, T2, and T3) treated with allogeneic PRP (six donors) for 96 hours, normalised to the mean of GAPDH and TBP () given as medians and 25–75 percentiles.
Scleraxis (SCX), decorin (DCN), tenomodulin (TNMD), cartilage oligomeric protein (COMP), aggrecan (ACAN), SRY (sex determining region Y)-box 9 (SOX9), collagen type I alpha 1 (COL1A1), collagen type 3 alpha 1 (COL3A1), collagen type II alpha 1 (COL2A1), hyaluronan synthase 2 (HAS2), interleukin-1, beta (IL-1b), interleukin-6 (IL-6), interleukin-8 (IL-8), cytochrome c oxidase 1 (COX1), cytochrome c oxidase 2 (COX2), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and TATA box binding protein (TBP).